Every healthcare company we've ever looked at has a clinical advisory board. Most of them are cosmetic. The advisors are on the website, their names appear in pitch decks, they get a modest equity grant, and then they answer two emails a year and attend one dinner if the company can afford to fly them somewhere. This is not a clinical advisory board. It's a credential-borrowing exercise, and experienced investors recognize it immediately.
The clinical advisory boards that actually change company trajectories are structured differently. They're not assembled to impress anyone — they're assembled to answer specific questions the company doesn't yet have the capability to answer internally. When we see one of those, it's genuinely one of the strongest early signals that a founding team knows what they're building and where the hard problems are.
Start with the question, not the name
The most common mistake in building a clinical advisory board is starting with who you can recruit. The better question is: what do we most need to know that we can't figure out ourselves? That question generates a requirements list. The requirements list tells you what kind of advisors to recruit. Advisors are hired to solve specific problems, not to provide general credibility.
A device company designing a spinal implant needs someone who has implanted hundreds of them and will tell you exactly what's wrong with your prototype in the first meeting. A digital health platform serving oncology needs a medical oncologist who also understands how hospital IT systems work and what clinical workflow actually looks like in a busy infusion center. A biotech developing a rare disease therapy needs someone who has run a clinical trial in that patient population and can tell you where the IND-enabling data package will get challenged.
These are specific people with specific expertise. They're often not the most famous names in the field. They're sometimes not professors at all — they might be the department head at a mid-sized regional health system who happens to manage 800 patients with the exact condition you're targeting. Fame is not what you need. Deep operational knowledge of the specific problem is what you need.
Structure the engagement, or it won't happen
Advisory relationships decay by default. The advisor has a full-time clinical job, academic obligations, multiple industry relationships, and a life outside medicine. Your company is not their priority, and that's fine — that's what the equity and advisory fee are for. What's not fine is assuming that good intentions will produce reliable engagement without structure.
Define deliverables when you recruit. Not vaguely — specifically. "We'd like four hours per quarter: two structured calls with the product team and two asynchronous reviews of clinical documents we'll send you in advance." That's something an advisor can budget time for and either agree to or decline. "We'd love your input whenever we need it" produces nothing of value.
The most effective CABs we've seen across our portfolio use a formal meeting cadence — usually quarterly, sometimes more frequent in active development phases — with a pre-circulated agenda, specific questions the company needs answered, and a designated follow-up lead who owns the action items. It runs like a board meeting, not a phone call.
The right advisor mix
A clinical advisory board that only includes academics is missing something. Academic physicians know the science and the clinical literature. They're often less aware of the operational realities of deploying a product in a health system that's under budget pressure, running Epic, and managing 22 competing clinical initiatives simultaneously.
The best CABs typically have three categories of advisor:
- Scientific/clinical domain experts — the people who know the disease biology, the clinical trial design requirements, and the published standard of care cold. Typically academic, frequently published in the relevant clinical journals.
- Operational practitioners — physicians or clinical leaders who are actively practicing in the environments where your product will be deployed. They tell you how it will actually be used, or why it won't be used at all.
- Regulatory and access experts — former FDA staff, payor medical directors, health system procurement leads. These people help you understand how your product gets approved, covered, and bought. Their value is usually understated by early-stage teams.
For a 5-6 person CAB, a rough mix of 2-2-2 across these categories works well. Skewing too heavily toward category 1 is the most common imbalance we see.
Compensation that aligns with what you're asking for
Standard advisory equity for clinical advisors is typically 0.1-0.25% over a 2-year vesting schedule, depending on stage and expected engagement level. This is reasonable for a low-engagement relationship. If you're asking for meaningful time commitments — quarterly board preparation, document review, trial design consultation — you should also pay cash. $2,000-$5,000 per day of formal engagement is a normal range for clinical advisors.
Some founders resist this because cash is tight. The argument we'd make: if you can't afford to pay an advisor for the work you're asking them to do, you're undervaluing the work or you haven't figured out what specifically you need. The solution is to narrow the ask and make it more targeted, not to expect substantial engagement without compensation.
One last thing
The CAB should evolve. The advisors you need to build your first prototype are probably not the same people you need to navigate a 510(k) submission, and definitely not the people you need to close your first hospital contract. Build with a time horizon. Treat advisory relationships as finite engagements with defined purposes, not as permanent honorary positions. The best advisors respect this — they know their expertise is relevant for a specific phase, and they'd rather have a focused high-impact relationship than a nominal one that fades.
